Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targeted therapies, we describe here the journey of CML, focusing on molecular pathways relating to signaling, metabolism and the bone marrow microenvironment. We highlight current strategies for combination therapies aimed at eradicating the CML stem cell; hopefully the final destination of this long voyage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 1×
“According to criteria by the World Health Organization, 10–19% blasts in peripheral blood or bone marrow are counted as AP, while > 20% blasts are considered a criterion for BC [19] (Figure 1).”
MethodAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 1×
“Other BCR-ABL1-independent, somatic mutations may also occur, especially in the genes ASXL1, DNMT3A, RUNX1 and TET2, whereby these may also have been present prior to the BCR-ABL1 rearrangement [79] and may represent clonal hematopoiesis in aged individuals [80].”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
The mechanisms of Hedgehog signalling and its roles in development and disease
Briscoe, J., & Thérond, P. P. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3598 · Cited by 1,751
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547 · cited 2×
“A recent study suggests that the life expectancy of CML patients treated with TKIs is close to the life expectancy of the general population [88,112].”
BackgroundMethodGranulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
The growing landscape of lysine acetylation links metabolism and cell signalling
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324
Direct measurement of local oxygen concentration in the bone marrow of live animals
Spencer, J. A., Ferraro, F., Roussakis, E., Klein, A., Wu, J., Runnels, J. M., Zaher, W., Mortensen, L. J., Alt, C., Turcotte, R., et al. (2014) · Nature · doi:10.1038/nature13034 · Cited by 1,167
Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5797 · Cited by 416
Giustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4336 · Cited by 403 · cited 2×
“The identification of the different LSC subgroups may allow predictions on which patients will develop resistance or progress to BC [22].”
BackgroundCancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
Hattori, A., Tsunoda, M., Konuma, T., Kobayashi, M., Nagy, T., Glushka, J., Tayyari, F., McSkimming, D., Kannan, N., Tojo, A., et al. (2017) · Nature · doi:10.1038/nature22314 · Cited by 401
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225 · cited 1×
“The dual inhibition of c-Myc and p53 had a superior effect in inducing apoptosis in CML cells, while no significant effect was observed for normal CD34+ cells [34].”
BackgroundDipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., et al. (2014) · Blood · doi:10.1182/blood-2013-10-536078 · Cited by 223 · cited 1×
“• (a) the sialic acid receptor CD33, which was expressed in CP LSC but only variably in BP LSC [23], • (b) the scavenger receptor CD36, expressed on primitive CML cells with decreased imatinib sensitivity [24] and on BC LSC in proximity to adipose tissue, whereby it mediates fatty acid uptake and oxidation [25], • (c)…”
BackgroundActivation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood · doi:10.1182/blood-2016-07-728873 · Cited by 154 · cited 2×
“• (a) the sialic acid receptor CD33, which was expressed in CP LSC but only variably in BP LSC [23], • (b) the scavenger receptor CD36, expressed on primitive CML cells with decreased imatinib sensitivity [24] and on BC LSC in proximity to adipose tissue, whereby it mediates fatty acid uptake and oxidation [25], • (c)…”
BackgroundKinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0684-5 · Cited by 67
D'Adda, M., Farina, M., Schieppati, F., Borlenghi, E., Bottelli, C., Cerqui, E., Ferrari, S., Gramegna, D., Pagani, C., Passi, A., et al. (2019) · Cancer · doi:10.1002/cncr.31977 · Cited by 64
Metadata
- Authors
- Minciacchi, V. R., Kumar, R., & Krause, D. S.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-01-10
- Volume
- 10
- Issue
- 1
- Pages
- 117
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3118839080
- Cited by
- 180
- References
- 21
- FWCI
- 18.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.